PMID- 1468553
OWN - NLM
STAT- MEDLINE
DCOM- 19930125
LR  - 20190620
IS  - 0014-5793 (Print)
IS  - 0014-5793 (Linking)
VI  - 314
IP  - 3
DP  - 1992 Dec 21
TI  - Inhibition of passive cutaneous anaphylaxis by synthetic human immunoglobulin E 
      peptide fragments.
PG  - 229-31
AB  - In an attempt to determine the regions responsible for type I immediate 
      hypersensitivity, a total of 42 peptide fragments, which cover the CH3-CH4 
      domains in human immunoglobulin E (IgE), were chemically synthesized. Several 
      peptide fragments located in the amino acid sequences Ala329-Thr357 and 
      Arg419-Ala463, inhibited passive cutaneous anaphylaxis (PCA) in vivo. In order to 
      pinpoint the sites responsible for the inhibition of the PCA reaction, various 
      fragment peptides in these two regions were synthesized. As a result, residues 
      Pro343-Leu348, Pro426-Thr433, and Ser456-Thr461 were suggested to be involved in 
      type I immediate hypersensitivity.
FAU - Nio, N
AU  - Nio N
AD  - Central Research Laboratories, Ajinomoto Co., Kawasaki, Japan.
FAU - Seguro, K
AU  - Seguro K
FAU - Ariyoshi, Y
AU  - Ariyoshi Y
FAU - Ishii, K
AU  - Ishii K
FAU - Nakamura, H
AU  - Nakamura H
LA  - eng
PT  - Journal Article
PL  - England
TA  - FEBS Lett
JT  - FEBS letters
JID - 0155157
RN  - 0 (Immunoglobulin Constant Regions)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Amino Acid Sequence
MH  - Animals
MH  - Binding Sites
MH  - Humans
MH  - Hypersensitivity, Immediate/*immunology/prevention & control
MH  - Immunoglobulin Constant Regions/immunology
MH  - Immunoglobulin E/*immunology
MH  - Male
MH  - Mice
MH  - Molecular Sequence Data
MH  - Passive Cutaneous Anaphylaxis/*immunology
MH  - Rats
MH  - Rats, Wistar
EDAT- 1992/12/21 00:00
MHDA- 1992/12/21 00:01
CRDT- 1992/12/21 00:00
PHST- 1992/12/21 00:00 [pubmed]
PHST- 1992/12/21 00:01 [medline]
PHST- 1992/12/21 00:00 [entrez]
AID - 10.1016/0014-5793(92)81477-4 [doi]
PST - ppublish
SO  - FEBS Lett. 1992 Dec 21;314(3):229-31. doi: 10.1016/0014-5793(92)81477-4.